Advancing the use of RWE with our research collaborators
Flatiron RWD has been used in projects across the drug development life cycle
Discovery & early development
Our RWD demonstrated that STK11 and KEAP1 mutations are negatively associated with real-world outcomes in both chemotherapy and PD-1/PD-L1 checkpoint inhibitors-treated NSCLC patients.
Our RWD can help inform the design of randomized controlled trials, such as by informing the selection of inclusion/exclusion criteria.
To inform regulatory decision making, RWD needs to be fit-for-purpose and tailored to specific regulatory and clinical contexts. Our RWD has provided supportive evidence to inform regulatory decision making.
Our RWD was used to help assess the safety of a drug in breast cancer patients with a certain type of heart failure, leading to a favorable label update in Europe and the U.S.
HTA bodies around the world assessed our RWD to characterize the natural history of a disease as part of reimbursement evaluations for novel therapies.
Real-World Evidence Library
Your destination for the latest thought leadership on real world data uses, applications and case studies.
More than 20 of the world’s top biopharma companies use Flatiron real-world data products to support their R&D pipelines and enhance their understanding of real-world cancer care.
Add-ons to our products:
Real-world outcome variables
Flatiron’s real-world outcome variables, used to derive real-world endpoints, account for the inherent complexities of patient outcomes specific to each cancer type.